According to the latest report by IMARC Group, titled “Tuberculosis Diagnostics Market Report by Disease Stage (Latent TB, Active TB), Test Type (Radiographic Test, Laboratory Test, Nucleic Acid Testing, Cytokine Detection Test, Drug Resistance Test, and Others), End-User (Hospitals and Clinics, Diagnostics and Research Laboratories, and Others), and Region 2025-2033,” the global tuberculosis diagnostics market reached a value of USD 2.6 Billion in 2024. Tuberculosis (TB) diagnostics refer to testing and detecting TB bacteria in the body, which usually attack the lungs but can damage other parts of the body in severe cases. The TB skin test (TST) and blood tests are the most commonly used diagnostic tool for TB. After an individual is found to be infected with the TB bacteria, several other tests, such as a chest X-ray and rapid sputum tests, are performed to see if the person has a latent TB infection or TB disease.
Global Tuberculosis Diagnostics Market Trends:
The market is primarily driven by the rapid proliferation of multi-drug resistant (MDR) tuberculosis. It is caused by bacteria that are resistant to isoniazid and rifampicin, which are considered to be among the most potent antimicrobial drugs for TB. The growing awareness among the masses about different diagnostic procedures and significant improvements in the healthcare infrastructure are also contributing to the market growth. Besides this, governments and several healthcare organizations are undertaking initiatives to control the proliferation of TB by increasing the screening and diagnosis rates of the disease worldwide. Moreover, the development of advanced diagnostic methods, such as interferon-gamma release assay (IGRA), cytokine detection assay and serological tests, have also encouraged patients to opt for TB diagnostics. These tests yield accurate results in a shorter time span while employing a smaller biological sample. Looking forward, IMARC Group expects the market to reach USD 3.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.01% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Disease Stage, Test Type, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Alere Inc., Becton Dickinson and Company, BioMérieux, Cepheid Inc., Epistem Ltd., Roche Holding AG, Hain Lifescience GmbH, Hologic Inc., QIAGEN GmbH, Siemens, Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal